文献速递糖尿病肥胖与代谢综合征

抗糖尿病药物与新发抑郁:一项全国性人群研究

Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study.
PubMed 文献 · Diabetes Care · 2020-09-25

该研究联合丹麦四个全国性登记数据库,纳入2005年全部丹麦人群并随访至2015年,分析20种最常用口服抗糖尿病药及胰岛素与新发抑郁的关联。结果显示持续使用二甲双胍及含二甲双胍的联合方案与新发抑郁率降低相关,吡格列酮无此关联,其他药物及胰岛素均无显著关联。

要点

  • 持续使用二甲双胍及含二甲双胍的联合方案与新发抑郁率降低相关。
  • 吡格列酮、其他口服抗糖尿病药及胰岛素与新发抑郁无显著关联。
  • 对于有抑郁风险(既往抑郁/焦虑或家族史)的2型糖尿病患者,处方时可参考二甲双胍的潜在获益。

核心结论

  • 基于真实世界的人群数据提示二甲双胍对新发抑郁率有正面影响。
  • 该证据可用于指导有抑郁风险的2型糖尿病患者的处方决策,包括既往有抑郁或焦虑以及有抑郁家族史的患者。

研究设计与样本

  • 联合丹麦四个全国性人群登记数据库,纳入2005年全部丹麦人群并随访至2015年。
  • 分析20种最常用口服抗糖尿病药与新发抑郁的关联,并纳入胰岛素作为比较。
  • 采用Cox回归模型分析。

主要发现

  • 持续使用二甲双胍及含二甲双胍的联合方案与新发抑郁率降低相关。
  • 吡格列酮与新发抑郁率降低无关联。
  • 其他抗糖尿病药物及胰岛素与新发抑郁无显著关联。

关键数值与推荐

  • 新发抑郁结局包括:因抑郁障碍在精神病医院住院或门诊确诊;或抑郁诊断与抗抑郁药使用的联合指标。
  • 共纳入360,205名口服抗糖尿病药使用者及64,582名胰岛素使用者。

临床怎么用

  • 对于有抑郁风险的2型糖尿病患者(包括既往抑郁或焦虑以及有抑郁家族史者),处方二甲双胍可能带来额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes is associated with an increased risk of depression. Some antidiabetes agents, specifically metformin and pioglitazone, have been suggested to have beneficial effects on depression, but associations between antidiabetes drugs and depression have not been systematically investigated. RESEARCH DESIGN AND METHODS: We combined four Danish population-based registers to investigate whether the 20 most widely used orally administered antidiabetes drugs were associated with an altered risk of incident depression. Analyses of insulin were included for comparisons. All persons in Denmark in 2005 were included in the study and followed until 2015. Two different outcome measures of incident depression were included: 1) a diagnosis of depressive disorder at a psychiatric hospital as an inpatient or outpatient and 2) a combined measure of a diagnosis of depression or use of antidepressants. Data were analyzed using Cox regression models. RESULTS: A total of 360,205 individuals using orally administered antidiabetes drugs and 64,582 using insulin at any time during the study period were included in the analyses. Continued use of metformin and combinations of drugs including metformin were associated with decreased rates of incident depression. Pioglitazone was not associated with a decreased rate of incident depression. No other antidiabetes drugs or insulin showed significant associations with depression. CONCLUSIONS: Real-life population-based data suggest a positive effect of metformin on depression rates. This evidence should be used in guiding prescriptions for patients with type 2 diabetes who are at risk for developing depression, including those with prior depression or anxiety and patients with a family history of depression.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kessing LV, Rytgaard HC, Ekstrøm CT, et al. Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. Diabetes Care. 2020. PMID: 32978179. doi:10.2337/dc20-1561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。